Types of c-myc rearrangements and β2-microglobulin (β2-m) levels
| Variable . | Germline c-myc* . | Classic t(8;14) . | Classic t(8;22) . | Other c-myc partners . | Nonclassic t(8;14)† . | All c-myc rearrangements . |
|---|---|---|---|---|---|---|
| No 14q32 rearrangement | 106 | 0 | 2 | 11 | 0 | 13/119 (11) |
| t(4;14)(p16;q32) | 46 | 1 | 1 | 12 | 0 | 14/60 (23) |
| t(11;14)(q13;q32) | 98 | 2 | 1 | 14 | 0 | 17/115 (15) |
| t(14;16)(q23;q32) | 12 | 1 | 0 | 1 | 0 | 2/14 (14) |
| 14q32 rearrangement with other partners | 260 | 8 | 4 | 30 | 3 | 45/302 (14) |
| No chromosome 13 deletion | 273 | 7 | 2 | 35 | 3 | 47/317 (15) |
| Chromosome 13 deletion | 249 | 5 | 6 | 33 | 0 | 44/293 (15) |
| β2-m less than or equal to 3 mg/L | 260 | 4 | 3 | 20 | 2 | 29/287 (10) |
| β2-m greater than 3 mg/L | 262 | 8 | 5 | 48 | 1 | 62/323 (19) |
| Variable . | Germline c-myc* . | Classic t(8;14) . | Classic t(8;22) . | Other c-myc partners . | Nonclassic t(8;14)† . | All c-myc rearrangements . |
|---|---|---|---|---|---|---|
| No 14q32 rearrangement | 106 | 0 | 2 | 11 | 0 | 13/119 (11) |
| t(4;14)(p16;q32) | 46 | 1 | 1 | 12 | 0 | 14/60 (23) |
| t(11;14)(q13;q32) | 98 | 2 | 1 | 14 | 0 | 17/115 (15) |
| t(14;16)(q23;q32) | 12 | 1 | 0 | 1 | 0 | 2/14 (14) |
| 14q32 rearrangement with other partners | 260 | 8 | 4 | 30 | 3 | 45/302 (14) |
| No chromosome 13 deletion | 273 | 7 | 2 | 35 | 3 | 47/317 (15) |
| Chromosome 13 deletion | 249 | 5 | 6 | 33 | 0 | 44/293 (15) |
| β2-m less than or equal to 3 mg/L | 260 | 4 | 3 | 20 | 2 | 29/287 (10) |
| β2-m greater than 3 mg/L | 262 | 8 | 5 | 48 | 1 | 62/323 (19) |
Values are numbers (%) of patients.
Germline c-myc indicates that no rearrangement was observed with use of the set of c-myc telomeric and centromeric probes.
Nonclassic t(8;14) refers to patients who hadc-myc–IgH fusion but lacked any c-mycrearrangement on analysis with the c-myc telomeric andc-myc centromeric set of probes.